Skip to main content
Evidence Snapshot

Histamine H4 receptor

CHEMBL3759 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:23Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3759
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Histamine H4 receptor as ChEMBL target CHEMBL3759, mapped to UniProt Q9H3N8. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Histamine H4 receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL3759
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q9H3N8
Histamine H4 receptor
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Histamine H4 receptor matters

As of 2026-09-14

Histamine H4 receptor is reviewed as Histamine H4 receptor (UniProt Q9H3N8); Histamine H4 receptor shows clinical signal disease relevance led by atopic eczema. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 18 approved drugs, 2689 compounds, and 476 assays, with lead potency reaching pChEMBL 10.5.

Disease context
atopic eczema

Histamine H4 receptor shows clinical signal disease relevance led by atopic eczema. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ADRIFORANT.

Start review with atopic eczema because it currently carries clinical signal support. Linked drugs include ADRIFORANT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Clinical signal 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 18 approved drugs, 2689 compounds, and 476 assays for this target. The dominant activity type is KI. CHEMBL1915536 is the current potency anchor at pChEMBL 10.5.

Use CHEMBL1915536 as the tractability anchor when discussing potency (pChEMBL 10.5).

Activity source · ChEMBL 36 via Core Engine
18 approved pChEMBL 10.5
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Histamine H4 receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q9H3N8, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why atopic eczema is currently treated as clinical signal support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2689
Total Compounds
476
Total Assays
18
Approved Drugs
IC50: 219.0, KI: 2112.0, EC50: 414.0, KD: 170.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL1915536
 10.5 Ki —
No preferred name
CHEMBL1770975
 10.4 Ki —
No preferred name
CHEMBL3393547
 10.1 Kd —
No preferred name
CHEMBL1914541
 10.0 Ki —
No preferred name
CHEMBL3236561
 10.0 Kd —

Approved Drugs

Structure Compound First Approval
HISTAMINE DIHYDROCHLORIDE
CHEMBL1533310
 2008
PRAMIPEXOLE
CHEMBL301265
 1997
CLOZAPINE
CHEMBL42
 1989
LOXAPINE
CHEMBL831
 1975
HISTAMINE
CHEMBL90
 1939
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:23Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3759